Investigators reported topline efficacy from two Phase 3 trials, REMODEL-1 and REMODEL-2, evaluating Novartis’ oral agent remibrutinib in patients with relapsing multiple sclerosis.
The study team observed reductions in the annualized relapse rate of 35.2% in one trial and 31.2% in the other when remibrutinib was compared against Sanofi’s approved oral therapy Aubagio.
Heinz Wiendl, a neurologist who presented the findings at an MS conference in Toronto, translated those effect sizes into a clinical frame by estimating roughly one relapse every 13 years under the trial assumptions.
The STAT report presented these figures as the primary efficacy takeaway. The source did not provide additional trial metrics in the published summary: dosing regimens, sample sizes, baseline characteristics, or statistical significance measures were not reported in the article.
Data in the STAT piece placed remibrutinib’s outcomes beside results from a competing Bruton's tyrosine kinase inhibitor program. The authors noted that Roche’s fenebrutinib reduced relapse rates by more than 50% versus Aubagio in its own pivotal studies.
That margin, as reported, positions fenebrutinib with a larger point estimate for relapse reduction than remibrutinib’s reported 31–35% range. The STAT article framed the comparison directly: remibrutinib did not achieve the same magnitude of relapse reduction as fenebrutinib in the respective pivotal trials.
The source did not provide head-to-head data or cross-trial statistical adjustments; readers must therefore interpret the relative differences as descriptive, based on separate trial reports rather than randomized comparisons.
The STAT summary described remibrutinib as having a “cleaner safety profile” relative to what reporters described as competitors’ safety signals. The study team and presenters, according to the article, emphasized tolerability as a potential competitive advantage for Novartis’ agent.
The article did not enumerate specific adverse events, serious adverse event rates, laboratory abnormalities, infection signals, or discontinuation rates. In other words, the source conveyed a qualitative safety judgment but did not publish the granular safety data that clinicians typically seek when evaluating a new MS therapy.
The STAT piece provided concise topline efficacy percentages and a comparative frame against fenebrutinib, but it omitted several trial details that are important for clinical interpretation. The article did not report dosing schedules, sample sizes, baseline relapse rates, demographic breakdowns, MRI outcomes, statistical significance values, or a full adverse-event table.
The authors also did not describe regulatory status or next steps for remibrutinib in terms of filings, submissions, or predicted review timelines. Presentation at the Toronto MS conference was the venue for the topline release; no primary manuscript or clinicaltrials.gov placard was referenced in the STAT summary.
These gaps limit direct clinical appraisal. Without access to the full dataset or a peer-reviewed report, clinicians cannot evaluate the robustness of the effect, the consistency across subgroups, or the balance of benefit and risk beyond the article’s qualitative descriptions.
Limitations and unanswered questions
The STAT article is a concise news summary of conference-presented results. It documented the percent reductions in relapse rate for remibrutinib and the comparative efficacy claim for fenebrutinib, but it did not provide the underlying trial architecture or detailed safety metrics.
Key unanswered clinical questions remain: what were the absolute relapse rates and event counts? What were the safety-event frequencies and types? How durable were the effects over time, and how did MRI lesion outcomes behave? The source did not report regulatory plans or submission timelines for remibrutinib.
Clinicians and decision-makers will need the full trial reports, safety appendices, or a peer-reviewed manuscript to assess where remibrutinib fits in the evolving therapeutic options for relapsing multiple sclerosis. The STAT summary ends on the presented topline numbers; it did not provide the comprehensive datasets that would answer those open questions.